Mar 27, 2025, 08:00
OHMX.bio joins BRECISE to revolutionize prostate and bladder cancer diagnostics
OHMX.bio shared a post on LinkedIn:
“OHMX.bio joins BRECISE to revolutionize cancer diagnostics
OHMX.bio is proud to be part of the BRECISE project, a five-year research initiative co-funded by the Innovative Health Initiative (IHI) under Horizon Europe.
This project focuses on multi-modal biomarker development for prostate and bladder cancer, aiming to refine personalized treatment strategies using Next-Generation Sequencing (NGS), AI, and ex vivo drug testing.
Our role?
At OHMX.bio, we contribute with:
- Advanced sequencing to generate high-quality genomic data
- Integrated bioinformatics to identify clinically relevant biomarkers
- Quality and compliance to meet ISO and GCLP standards
With 30 partners from academia, industry, and healthcare, BRECISE is set to transform precision oncology. We are excited to collaborate and drive real clinical impact!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 21, 2025, 20:46
Apr 21, 2025, 20:30
Apr 21, 2025, 20:11
Apr 21, 2025, 19:55
Apr 21, 2025, 19:12
Apr 21, 2025, 18:19
Apr 21, 2025, 18:00
Apr 21, 2025, 17:40
Apr 21, 2025, 17:35
Apr 21, 2025, 17:29